author-photo

O. Hataji

8

Papers

10

Citations

Citation Trend

Filter By

Papers (6) Sort By

Journal Conference Others

A multicenter cohort study of osimertinib compared with afatinib as first-line treatment for EGFR-mutated non-small-cell lung cancer from practical dataset: CJLSG1903

2021
Show All
- Source
- Cite
- Save
Citations (2)
P1.01-34 Docetaxel Plus Ramucirumab with Prophylactic PEG-G-CSF Support for Chemo-NaïVe Elderly NSCLC Patients: A Phase II Study (WJOG9416L)

2018 Journal of Thoracic Oncology
Show All
- Source
- Cite
- Save
Citations (0)
1445PA phase II study of first-line afatinib for patients aged 75 or older with EGFR mutation-positive advanced non-small cell lung cancer: North East Japan study group trial NEJ027

2018 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (3)
P1.01-40 Randomized Phase II Study of Docetaxel Plus Bevacizumab or Pemetrexed Plus Bevacizumab for Elderly pts with Untreated Advanced NSCLC: TORG1323

2018 Journal of Thoracic Oncology
Show All
- Source
- Cite
- Save
Citations (0)
1455PComparative analysis of overall survival using propensity score between first- and second-generation EGFR-TKI: Real world data of 1354 patients with EGFR mutant NSCLC

2018 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (4)
P1.03-027 Randomized Phase 2 Study Comparing CBDCA+PTX+BEV and CDDP+PEM+BEV in Treatment-Naïve Advanced Non-Sq NSCLC (CLEAR Study)

2017 Journal of Thoracic Oncology
Show All
- Source
- Cite
- Save
Citations (1)